Biomoda To Participate in OneMedPlace New York Finance Forum
06.29.2010 — 8:00 am
Albuquerque, NM (June 29, 2010) – Cancer diagnostics company Biomoda, Inc. (OTC BB: BMOD) will present on its proprietary CyPath® diagnostic assay for the detection of early-stage cancers at OneMedPlace’s mid-year finance forum in New York on Wednesday, June 30, 2010.
The OneMedPlace conference will connect 75 private and microcap companies with European and U.S. institutional investor groups interested in the healthcare and biotechnology sectors. The focus in New York will be on accessing new sources of capital.
“The OneMedPlace forum gives us an opportunity to introduce our technology to an audience that understands the global market potential for a non-invasive, inexpensive, accurate screening diagnostic assay for cancer,” Biomoda President John Cousins said. “Lung cancer is our first target because it’s the deadliest cancer worldwide and hard to diagnose in the early stages, but we are currently taking a look at expanding our studies to cervical and breast cancer.”
Cousin’s presentation will be Webcast at www.onemedplace.com/forum/webcast.php at approximately 3:20 Eastern Daylight Time on Wednesday, June 30.
Biomoda recently completed patient enrollment and sample collection for the Phase II pilot study on its porphyrin-based compound as a diagnostic tool for early-stage lung cancer. The CyPath® labeling solution preferentially binds to cancer cells and causes them to fluoresce red under ultraviolet light. Pending Food and Drug Administration approval, CyPath® is for investigational use only. Biomoda is also pursuing a CE mark to commercialize CyPath® in the European Union.
The OneMedPlace Advisory Board said companies invited to participate in the mid-year forum at New York’s Roosevelt Hotel must have breakthrough technologies based on strong science, experienced management teams with a proven track record, strong and comprehensive IP portfolios, and partnerships with leading academic institutions and strategic players. “We are pleased to be included in this peer group,” Cousins said.